Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | DRD4 | P21917 | 4/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20157283 | 0.93 | KDM5A (0.53) | HTR1ADRD2DRD4GRM5GPR119 | |
| SCHEMBL20140687 | 0.93 | KDM5A (0.53) | HTR1ADRD2DRD4GRM5GPR119 | |
| SCHEMBL16291592 | 0.87 | GPR119 (0.50) | GPR119TRPV3KDM4EMAPTTHRB | |
| SCHEMBL29518419 | 0.87 | GPR119 (0.50) | GPR119TRPV3KDM4EMAPTTHRB | |
| SCHEMBL31232914 | 0.87 | GRM5 (0.48) | HTR1ADRD2DRD4GRM5GPR119 | |
| SCHEMBL3001502 | 0.87 | GRM5 (0.48) | HTR1ADRD2DRD4GRM5GPR119 | |
| SCHEMBL14240648 | 0.86 | TRPV3 (0.51) | GPR119TRPV3KDM4EMAPTTHRB | |
| SCHEMBL5352510 | 0.86 | TRPV3 (0.51) | HTR1ADRD2DRD4GPR119TRPV3 | |
| SCHEMBL20266403 | 0.86 | STS (0.51) | GPR119TRPV3KDM4EMAPTTHRB | |
| SCHEMBL2878345 | 0.86 | TRPV3 (0.53) | HTR1ADRD2DRD4GPR119TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | HTR1A 955/4885DRD2 2225/4885DRD4 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.